Menlo Park, CA-based Avalanche Biotechnologies, Inc. (AAVL - Analyst Report) is a development-stage biopharmaceutical company with a focus on gene therapies targeting prevalent ophthalmic diseases with significant unmet need like wet age-related macular degeneration (AMD) as well as rare genetic ophthalmic diseases.

Being a development-stage company, Avalanche does not have any approved product in its portfolio yet. In this scenario, investors are expected to keep an eye on pipeline development at the company, apart from the usual bottom-line numbers.

Avalanche has a disappointing earnings track record as it missed estimates in three of the last four quarters, with a negative average earnings surprise of 20.3%.

Currently, Avalanche has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Avalanche reported a loss of 55 cents in the fourth quarter of 2015, wider than our consensus estimate of a loss of 40 cents.

Revenue: Avalanche earned collaboration revenues of $960,000 revenues in the reported quarter. .

Key Stats: Last month, Avalanche announced that it will acquire Annapurna Therapeutics, a gene therapy company with four candidates in development. These candidates include a program for the potential treatment of alpha 1 antitrypsin deficiency which is expected to enter clinic by the end of 2016 and a candidate for the potential treatment of hereditary angioedema which is expected to enter clinic in 2017.